Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Insulin detemir (Levemir®)		Prescribe by brand name
Insulin glargine (lantus®)	TA53 - Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargene	Extremely high relative cost. Prescribe by brand name.
Insulin glargine 100 units/ml (Abasalgar®)		Prescribe by brand name. First line for new patients initiated on insulin glargine 100 units/ml.
Insulin glulisine (Apidra)		Prescribe by brand name
Insulin humalog® mix 25		Prescribe by brand name
Insulin humalog® mix 50		Prescribe by brand name
Insulin humulin I® injection		Prescribe by brand name
Insulin humulin S® injection		Prescribe by brand name
Insulin humulin® M3 injection		Prescribe by brand name
Insulin hypurin® bovine isophane injection		For existing patients only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.